Testing a new NK cell therapy for solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called LEU011, which uses your own immune cells (NK cells) to attack solid tumors that have a specific protein. It is for people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is confirmed by a biopsy or lab test.
- You are 18 years or older.
- Your cancer has come back or not responded to treatment, and there are no standard treatments left that can help.
- Your tumor has a specific protein (NKG2DL) on at least 10% of its cells.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are fully active or able to do light work (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.